Please assess the completion status of the following clinical trial:

Trial Title: Testosterone Treatment for Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men, age 18-65, with a diagnosis of clinically definite relapsing remitting multiple sclerosis.~2. Relapsing remitting patients who have declined or not tolerated treatment with beta interferon (Betaseron, Avonex) or glatiramer acetate, copolymer-1 (Copaxone).~3. At least one relapse in the two years prior to entry. Relapse will be defined historically as definite worsening of a previous symptom (over 0-3 days) or development of a new symptom (over 0-3 days).~4. Not in an intercurrent relapse.~5. Expanded Disability Status Score (EDSS) = 0.0 to 5.0.~6. The patients must have a significant T2 burden of disease on screening cerebral MRI as defined by T2 lesion loads greater than 7.5cm3.~7. Must live within 100 miles of UCLA.~8. Must be willing and able to receive an initial screening cerebral MRI, a baseline MRI and monthly cerebral MRIs (with and without gadolinium) for a total period of 12 months (6 months prior to treatment and 6 months during treatment).~Exclusion Criteria:~1. Males unable to fulfill the above criteria and all female patients.~2. Males who have been on sex hormone treatment including androgens, estrogens, or anti-estrogens for hypogonadism or other medical condition during the 12 months prior to study.~3. Males who have taken DHEA during the 3 months prior to study.~4. Patients who have thrombosis, serious cardiac, pulmonary, renal, gastrointestinal, hepatic, immunologic, infectious, neoplastic (with particular focus on patients with known or suspected estrogen or testosterone-dependent tumors), or urologic disease (with a particular focus on patients with a history of prostatic hypertrophy/nodules).~5. Patients with an abnormal prostate as evidenced by prostatic masses or induration on rectal examination or prostate ultrasonography or elevated levels of prostatic specific antigen (PSA 4 ng/ml or higher).~6. Patients with testicular mass on exam.~7. Patients with hematocrit greater than 50%~8. Patients with major psychiatric illness (e.g. manic depressive states, schizophrenia)~9. Patients with active alcoholism.~10. Patients with a history of drug abuse within the past five years.~11. Patients who are greater than 130% or less than 80% of their ideal body weight based on Metropolitan Life Tables.~12. Patients with generalized skin disease that may effect absorption of testosterone (e.g. psoriasis) or a known skin intolerance to alcohol.~13. Patients with prolactin \> 40 mcg/L.~14. Patients with a cholesterol level greater than 300 mg/dl.~15. Patients with other conditions that would interfere with assessing neurologic functions such as deforming arthritis or a major amputation.~16. Patients who have received treatment with beta interferon (Betaseron or Avonex), glatiramer acetate copolymer-1 (Copaxone), ACTH, corticosteroids, intravenous immunoglobulins (IVIG), or plasma exchange in the three months preceding enrollment~17. Patients who have received treatment with azathioprine, cyclophosphamide, methotrexate, mitoxantrone, cyclosporin A or experimental therapies in the six months preceding enrollment.~18. Patients who have been treated with total lymphoid irradiation, monoclonal antibody, T cell vaccination, cladribine or bone marrow transplantation.~19. Patients who have positive titers to HIV1,2; HTLV1; or VDRL.~20. Patients who have clinical evidence of Lyme disease.~21. Patients who are mentally or emotionally incompetent in the opinion of the examining neurologist or unable to give informed consent, or to understand and comply with the study protocol.~22. Patients with certain artificial heart valves, pacemakers, or other metallic/electronic material in their bodies.~23. Patients with known hypersensitivity to gadolinium-DPTA.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- crossover treatment with Androgel (Type: EXPERIMENTAL): 6 months pretreatment, 12 months treatment intervention with Androgel 10 grams of gel containing 100mg of testosterone

Based on this trial design, predict the completion outcome and termination type (if applicable).